Akums Drugs enters into a joint association with Leiutis and Biophore for first-of-its-kind therapeutics

Contract drug manufacturing organisation (CDMO) major Akums Drugs and Pharmaceuticals Ltd has announced partnership with Leiutis Pharmaceuticals LLP and Biophore India Pharmaceuticals for research and development of a range of products for multiple therapies, in order to leverage the research expertise and combined manufacturing capacities to introduce first-of-its-kind products in India

The company expects that this association is set to bring succour in therapy areas of CNS disorders, Pain management, and Hormonal disorders, where there is a gap in meeting the needs of patients in an effective, safe, and convenient manner. It also leverages the strengths of each of the companies resulting in an innovation strategy creating a unique value proposition to doctors and patients in India.

This tripartite association will see Akums manufacture & commercialise the products created by Leiutis Pharmaceuticals LLP and API from Biophore. These unique products will be launched and marketed in India and the rest of the world with potential to bring about useful therapies and bridge the gaps in the treatment of ailments and diseases across the world.

The focus of the companies in this partnership is to synergise capabilities, leverage research and bring innovative products in specific therapeutic areas, within the next five years, both in India and other global markets and with the first few products expected to be commercialised in the next two years. The agreement was signed at the CPhI event and exhibition on November 30, 2022 at Greater Noida in the presence of Prof(Dr). Y.K Gupta, president AIIMS Bhopal & president AIIMS Jammu & Former Dean & HoD Pharmacology, AIIMS Delhi.

“A significantly large number of patients suffer from these diseases in India and globally, requiring treatment for several years and often having suboptimal experience with the available treatment options. In association with Leiutis and Biophore, we are committing to bringing unique products made available to the physicians and patients for improved clinical outcomes”, said Sanjeev Jain, founder, promoter and director, Akums.

Dr. Jagadeesh Babu Rangisetty, Founder and CEO of Biophore said, “It’s such an exciting prospect to partner with two other amazing organisations in the global pharma space. The aim is to combine our key competencies, capacities, and our passion for providing new therapies globally proven through clinical outcomes and to improve the lives of patients”.

“Innovative therapies should address two objectives; ameliorate suffering and improve quality of life. Innovation is a collaborative journey & I am very excited to be part of this journey. It gives me immense pride to mention that the products, technology, APIs, and manufacturing are developed and made in India,” said K Chandrasekhar, CEO of Leiutis Pharmaceuticals LLP.

Akums Drugs, claimed as India’s largest Contract Research and Manufacturing (CRAMS) organisation, currently manufactures around 12% of the country’s total medicinal requirements. The organisation deals in the manufacturing and export of formulations in a wide spectrum of dosage forms & therapeutic segments.

Akums with reach to different markets, operates 15 fully-certified, state-of-the-art manufacturing facilities across the country. This is coupled with the company’s expertise in manufacturing and commercializing virtually all types of formulations, such as tablets, capsules, oral liquids, injections, creams, ointments, etc.

Leiutis Pharmaceuticals LLP, a pharmaceutical product innovation company that creates innovative products that advance treatment in specific therapeutic areas has expertise in nanotherapeutics, and innovation which supports the next generation of speciality medicines. It has proprietary drug delivery technology, especially for the advancement of treatment in pain management, CNS disorders, cancer, immunomodulators, CVS disorders, hormonal disorders, and supportive care.

Biophore Pharmaceuticals Pvt Ltd, an established pharmaceutical company that develops and manufactures niche pharmaceutical products for the generic industry, has state-of-the-art, multipurpose Active Ingredient manufacturing facilities in India comply with cGMP standards and meet the requirements of US and EU Drug regulatory authorities. Its technology development centre in Hyderabad is equipped with infrastructure that facilitates the entire process of drug research from conceptualisation to regulatory submissions. The company has filed over 100 drug master files and 150 patents for its unique portfolio. Biophore is one of the world’s leading API companies, ranking in the top 10 US DMF filers with the US FDA in the last five years.